Intravenous Glucagon in Food Impaction?Use It or Lose It?

Fass, Ronnie; Dekel, Roy

doi:10.1007/s00455-003-0024-8

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,6,14,15 One author suggests that glucagon "may impede disimpaction" of EFBI. 16 Intravenous glucagon is also expensive (about US$70 per 1-mg vial). It is clear that glucagon commonly causes vomiting and therefore poses a risk of aspiration, esophageal perforation and increased morbidity.…”

Section: Resultsmentioning

confidence: 99%

Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction

Arora

Galich²

2009

CJEM

View full text Add to dashboard Cite

Esophageal foreign body impactions (EFBIs) are relatively rare in emergency medicine; patients rarely have them more than once. Indications for watchful waiting include a patent airway and the ability to clear secretions. However, in many cases, significant discomfort combined with patient expectations mandate early intervention to dislodge the foreign body. Endoscopy is the preferred definitive method of intervention for EFBI; however, most emergency physicians choose to apply one of several less invasive modes of therapy as firstline treatment. Pharmacologic agents that have been described for this purpose include glucagon, nifedipine, sublingual nitroglycerin, proteolytic enzymes and benzodiazepines. Among these, glucagon has become the most widely accepted in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction

Arora

Galich²

2009

CJEM

View full text Add to dashboard Cite

show abstract

Conservative management of oesophageal soft food bolus impaction

Hardman

Sharma

Smith

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Is current UK management of oesophageal food bolus obstruction evidence based? An e-mail survey and literature review

Price

Jones

Montgomery

2007

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

There is a great deal of variation in individual management of non-sharp oesophageal food bolus obstruction in the United Kingdom. An e-mail survey of consultants and specialist registrars in ENT was carried out to establish current UK practice. A review of the published literature was under-taken to establish whether current practice is evidence based. The majority of practitioners (95%) do not proceed immediately to rigid oesophagoscopy but use antispasmodic drugs (83%), most commonly hyoscine butylbromide (Buscopan) and diazepam, to try to induce spontaneous passage of the obstruction. There is currently no evidence in the published literature to support the use of these drugs. The use of Buscopan seems to have been encouraged by a misquoted reference in a prominent ENT textbook. Better evidence is needed to establish the best form of treatment for this relatively common problem.

show abstract

Intravenous Glucagon in Food Impaction?Use It or Lose It?

Cited by 4 publications

References 21 publications

Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction

Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction

Conservative management of oesophageal soft food bolus impaction

Is current UK management of oesophageal food bolus obstruction evidence based? An e-mail survey and literature review

Contact Info

Product

Resources

About